Company logo

MCRB - Seres Therapeutics, Inc.

NASDAQ -> Healthcare -> Biotechnology
Cambridge, United States
Type: Equity

MCRB price evolution
MCRB
(in millions $) 31 Mar 2024 31 Dec 2023 30 Sep 2023 30 Jun 2023
Current assets
Cash $119.61 $136.15 $178.1 $237.71
Short term investments
Net receivables $7.42 $8.67 $16.86 $7.56
Inventory $41.97 $29.65 $18.52 $5.34
Total current assets $165.18 $175.41 $214.39 $251.24
Long term investments $1.4 $1.4 $1.4 $1.4
Property, plant & equipment $124.78 $132.25 $131.67 $134.31
Goodwill & intangible assets
Total noncurrent assets $176.08 $183.19 $153.31 $155.15
Total investments $1.4 $1.4 $1.4 $1.4
Total assets $341.26 $358.6 $367.7 $406.39
Current liabilities
Accounts payable $5.22 $3.64 $8.96 $12.92
Deferred revenue $103.47 $103.09 $104.89 $98.56
Short long term debt $8.83 $6.68 $6.28 $5.47
Total current liabilities $98.48 $98.66 $79.22 $77.9
Long term debt $205.35 $207.26 $206 $207.45
Total noncurrent liabilities $302.52 $304.8 $303.6 $305.88
Total debt $214.18 $213.94 $212.28 $212.92
Total liabilities $401 $403.46 $382.82 $383.77
Shareholders' equity
Retained earnings -$1018.37 -$978.24 -$936.99 -$889.13
Other shareholder equity -$0
Total shareholder equity -$59.74 -$44.86 -$15.12 $22.61
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $136.15 $171.22 $188 $116.05
Short term investments $18.31 $110.7 $137.57
Net receivables $8.67 $9.39
Inventory $29.65
Total current assets $175.41 $194.76 $303.63 $268.78
Long term investments $1.4 $1.4 $1.9 $51.23
Property, plant & equipment $132.25 $133.97 $36.15 $22.94
Goodwill & intangible assets
Total noncurrent assets $183.19 $154.02 $51.23 $74.16
Total investments $1.4 $19.71 $112.6 $188.79
Total assets $358.6 $348.78 $354.86 $342.94
Current liabilities
Accounts payable $3.64 $17.44 $13.73 $4.02
Deferred revenue $103.09 $96.69 $103.82 $108.17
Short long term debt $6.68 $4.06 $6.61 $5.57
Total current liabilities $98.66 $85.6 $82.26 $46.41
Long term debt $207.26 $50.59 $42.6 $35.2
Total noncurrent liabilities $304.8 $252.41 $141.09 $121.78
Total debt $213.94 $162.59 $49.21 $40.77
Total liabilities $403.46 $338 $223.35 $168.19
Shareholders' equity
Retained earnings -$978.24 -$864.51 -$614.35 -$548.78
Other shareholder equity -$0.01 -$0.06 -$0.05
Total shareholder equity -$44.86 $10.78 $131.51 $174.75
(in millions $) 31 Mar 2024 31 Dec 2023 30 Sep 2023 30 Jun 2023
Revenue
Total revenue $0.06 $0.31 $126.47
Cost of revenue
Gross Profit $0.06 $0.31 $126.47
Operating activities
Research & development $21.7 $26.85 $28.25 $46.79
Selling, general & administrative $15.47 $17.23 $19.99 $28.05
Total operating expenses $39.59 $39.59 $47.72 $76.95
Operating income -$39.59 -$39.53 -$47.41 $49.52
Income from continuing operations
EBIT -$35.47 -$37.22 -$43.84 $49.74
Income tax expense
Interest expense $4.66 $4.03 $4.01 $3.19
Net income
Net income -$40.13 -$41.25 -$47.85 $46.55
Income (for common shares) -$40.13 -$41.25 -$47.85 $46.55
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $126.33 $7.13 $144.93 $33.22
Cost of revenue
Gross Profit $126.33 $7.13 $144.93 $33.22
Operating activities
Research & development $145.86 $172.92 $141.89 $90.57
Selling, general & administrative $87.74 $79.69 $69.26 $30.77
Total operating expenses $234.31 $253.62 $209.42 $121.34
Operating income -$107.98 -$246.49 -$64.49 -$88.13
Income from continuing operations
EBIT -$100.55 -$244.14 -$62.67 -$86.2
Income tax expense
Interest expense $13.18 $6.02 $2.91 $2.92
Net income
Net income -$113.72 -$250.16 -$65.58 -$89.13
Income (for common shares) -$113.72 -$250.16 -$65.58 -$89.13
(in millions $) 31 Mar 2024 31 Dec 2023 30 Sep 2023 30 Jun 2023
Net income -$40.13 -$41.25 -$47.85 $46.55
Operating activities
Depreciation $3.95 $4.05 $3.89 $3.7
Business acquisitions & disposals
Stock-based compensation $6.49 $5.09 $8.67 $13.49
Total cash flows from operations -$35.24 -$47.5 -$59.26 $65.98
Investing activities
Capital expenditures -$0.06 -$0.88 -$1.8 -$1.23
Investments $11.75
Total cash flows from investing -$0.06 -$0.88 -$1.8 $10.52
Financing activities
Dividends paid
Sale and purchase of stock $18.76 $6.43 $1.44 $7.66
Net borrowings $50.52
Total cash flows from financing $18.76 $6.43 $1.44 $58.18
Effect of exchange rate $0 $0
Change in cash and equivalents -$16.54 -$41.95 -$59.61 $134.68
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$113.72 -$250.16 -$65.58 -$89.13
Operating activities
Depreciation $15.11 $11.85 $9.22 $8.89
Business acquisitions & disposals
Stock-based compensation $34.1 $25.48 $20.22 $8.82
Total cash flows from operations -$117.35 -$228.82 $6.69 -$93.61
Investing activities
Capital expenditures -$7.97 -$9.82 -$9.57 -$0.59
Investments $18.56 $92.25 $73.65 -$158.3
Total cash flows from investing $10.58 $82.43 $64.09 -$158.89
Financing activities
Dividends paid
Sale and purchase of stock $21.19 $103.9 $2.13 $303.42
Net borrowings $50.52 $25.7 -$0.95
Total cash flows from financing $71.7 $129.6 $1.18 $303.42
Effect of exchange rate $0 -$0 -$0
Change in cash and equivalents -$35.07 -$16.79 $71.95 $50.92
Fundamentals
Market cap $148.11M
Enterprise value $242.68M
Shares outstanding 151.44M
Revenue $126.85M
EBITDA -$51.20M
EBIT -$66.79M
Net Income -$82.68M
Revenue Q/Q -100.00%
Revenue Y/Y 2.38K%
P/E ratio -1.79
EV/Sales 1.91
EV/EBITDA -4.74
EV/EBIT -3.63
P/S ratio 1.17
P/B ratio -2.48
Book/Share -0.39
Cash/Share 0.79
EPS -$0.55
ROA -22.44%
ROE 340.60%
Debt/Equity -8.99
Net debt/EBITDA -5.50
Current ratio 1.68
Quick ratio 1.25